{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:41:52Z","timestamp":1773798112039,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100\u00a0mg once weekly [QW] or 60\u00a0mg twice weekly), in combination with daratumumab (16\u00a0mg\/kg per label) and dexamethasone (40\u00a0mg QW) (SDd) in patients with relapsed refractory multiple myeloma (RRMM). Thirty\u2010four patients (median prior therapies, 3 [range, 2\u201010]) were enrolled; MM was refractory to proteasome inhibitor (PI) in 85%, immunomodulatory agent (IMiD) in 76%, both in 74%, and daratumumab in 6% of patients. Two dose\u2010limiting toxicities (DLTs) were reported in the selinexor 60\u00a0mg twice\u2010weekly cohort with no DLTs in the 100\u00a0mg QW cohort, making 100\u00a0mg QW the MTD and RP2D. Common treatment\u2010related adverse events included thrombocytopenia (70.6%), nausea (70.6%), fatigue (61.8%), anemia (61.8%), and neutropenia (50.0%). Overall response rate was 73% and median progression\u2010free survival 12.5 months in daratumumab\u2010na\u00efve patients. SDd was well tolerated and its promising efficacy suggests that further study of this PI\u2010 and IMiD\u2010free regimen in RRMM patients who had at least one prior line of therapy including a PI and an IMiD but whose disease is na\u00efve to daratumumab is warranted.<\/jats:p>","DOI":"10.1002\/jha2.122","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T12:04:46Z","timestamp":1604837086000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-5605","authenticated-orcid":false,"given":"Cristina","family":"Gasparetto","sequence":"first","affiliation":[{"name":"Duke Cancer Institute School of Medicine Duke University  Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Columbia University  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA  Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center  Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Tuchman","sequence":"additional","affiliation":[{"name":"University of North Carolina  Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-3669","authenticated-orcid":false,"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[{"name":"Dalhousie University and QEII Health Sciences Center  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba  Winnipeg Manitoba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[{"name":"Royal Victoria Hospital  Montreal Qu\u00e9bec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center  Omaha Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Swedish Cancer Center  Seattle Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"CIUSSS de l'Est de l'Ile de Montr\u00e9al Universit\u00e9 de Montr\u00e9al  Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Venner","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Southern Alberta Cancer Research Institute  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"NYPH Weill Cornell  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"Hackensack Meridian Health Hackensack University Medical Center  Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Richard","family":"Saint\u2010Martin","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dane","family":"Van Domelen","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Kai","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics  Newton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brea","family":"Lipe","sequence":"additional","affiliation":[{"name":"University of Rochester Medical College  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000163"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.200"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.03.002"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.172"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0085-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12428"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12969"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.11.022"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_9_22_1","unstructured":"Karyopharm Therapeutics Inc.: XPOVIO\u2122 (selinexor) [Package Insert] [Internet]. 2019. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212306s000lbl.pdf"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25368"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0488"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.03.001"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.7080"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8501"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.42"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122907"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122902"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0756-6"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_2_9_37_1","unstructured":"National Comprehensive Cancer Network (NCCN): Guidelines in oncology: Multiple Myeloma (Version 1.2021\u2010August 24 2020). [Internet]. 2020. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.12.026"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:45:24Z","timestamp":1693197924000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/jha2.122"],"URL":"https:\/\/doi.org\/10.1002\/jha2.122","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,8]]},"assertion":[{"value":"2020-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}